These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 38003841)

  • 1. Schizophrenia and Glutathione: A Challenging Story.
    Carletti B; Banaj N; Piras F; Bossù P
    J Pers Med; 2023 Oct; 13(11):. PubMed ID: 38003841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Reports on Redox Stress-Induced Mitochondrial DNA Variations, Neuroglial Interactions, and NMDA Receptor System in Pathophysiology of Schizophrenia.
    Beeraka NM; Avila-Rodriguez MF; Aliev G
    Mol Neurobiol; 2022 Apr; 59(4):2472-2496. PubMed ID: 35083660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of plasma glutathione in psychosis associated with schizophrenia and bipolar disorder in translational psychiatry.
    Nucifora LG; Tanaka T; Hayes LN; Kim M; Lee BJ; Matsuda T; Nucifora FC; Sedlak T; Mojtabai R; Eaton W; Sawa A
    Transl Psychiatry; 2017 Aug; 7(8):e1215. PubMed ID: 28892069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced antioxidant defense systems in schizophrenia and bipolar I disorder.
    Raffa M; Barhoumi S; Atig F; Fendri C; Kerkeni A; Mechri A
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):371-5. PubMed ID: 22841966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multimodal approach to studying the relationship between peripheral glutathione, brain glutamate, and cognition in health and in schizophrenia.
    Coughlin JM; Yang K; Marsman A; Pradhan S; Wang M; Ward RE; Bonekamp S; Ambinder EB; Higgs CP; Kim PK; Edwards JA; Varvaris M; Wang H; Posporelis S; Ma S; Tsujimura T; Edden RAE; Pomper MG; Sedlak TW; Fournier M; Schretlen DJ; Cascella NG; Barker PB; Sawa A
    Mol Psychiatry; 2021 Jul; 26(7):3502-3511. PubMed ID: 33077854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics.
    Lai CY; Scarr E; Udawela M; Everall I; Chen WJ; Dean B
    World J Psychiatry; 2016 Mar; 6(1):102-17. PubMed ID: 27014601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of oxidative stress biomarkers in drug‑free patients with schizophrenia and schizo-affective disorder.
    Guidara W; Messedi M; Naifar M; Maalej M; Grayaa S; Omri S; Ben Thabet J; Maalej M; Charfi N; Ayadi F
    Psychiatry Res; 2020 Nov; 293():113467. PubMed ID: 33198042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative Stress Biomarkers as a Predictor of Stage Illness and Clinical Course of Schizophrenia.
    Juchnowicz D; Dzikowski M; Rog J; Waszkiewicz N; Zalewska A; Maciejczyk M; Karakuła-Juchnowicz H
    Front Psychiatry; 2021; 12():728986. PubMed ID: 34867519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redox dysregulation in the pathophysiology of schizophrenia and bipolar disorder: insights from animal models.
    Kulak A; Steullet P; Cabungcal JH; Werge T; Ingason A; Cuenod M; Do KQ
    Antioxid Redox Signal; 2013 Apr; 18(12):1428-43. PubMed ID: 22938092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of oxidative stress in the pathophysiology of neuropsychiatric disorders].
    Nunomura A; Tamaoki T; Motohashi N
    Seishin Shinkeigaku Zasshi; 2014; 116(10):842-58. PubMed ID: 25672211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia.
    Kunz M; Gama CS; Andreazza AC; Salvador M; Ceresér KM; Gomes FA; Belmonte-de-Abreu PS; Berk M; Kapczinski F
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Oct; 32(7):1677-81. PubMed ID: 18657586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redox dysregulation, immuno-inflammatory alterations and genetic variants of BDNF and MMP-9 in schizophrenia: Pathophysiological and phenotypic implications.
    Ali FT; Abd El-Azeem EM; Hamed MA; Ali MAM; Abd Al-Kader NM; Hassan EA
    Schizophr Res; 2017 Oct; 188():98-109. PubMed ID: 28100419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular free water and glutathione in first-episode psychosis-a multimodal investigation of an inflammatory model for psychosis.
    Lesh TA; Maddock RJ; Howell A; Wang H; Tanase C; Daniel Ragland J; Niendam TA; Carter CS
    Mol Psychiatry; 2021 Mar; 26(3):761-771. PubMed ID: 31138893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are Advanced Oxidation Protein Products (AOPPs) Levels Altered in Neuropsychiatric Disorders? An Integrative Review.
    de Brum GF; Bochi GV
    Mol Neurobiol; 2024 Nov; 61(11):9043-9059. PubMed ID: 38580854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral phenotyping of glutathione-deficient mice: relevance to schizophrenia and bipolar disorder.
    Kulak A; Cuenod M; Do KQ
    Behav Brain Res; 2012 Jan; 226(2):563-70. PubMed ID: 22033334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for increased DNA damage repair in the postmortem brain of the high stress-response group of schizophrenia.
    Shishido R; Kunii Y; Hino M; Izumi R; Nagaoka A; Hayashi H; Kakita A; Tomita H; Yabe H
    Front Psychiatry; 2023; 14():1183696. PubMed ID: 37674553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice.
    Dean OM; van den Buuse M; Bush AI; Copolov DL; Ng F; Dodd S; Berk M
    Curr Med Chem; 2009; 16(23):2965-76. PubMed ID: 19689277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of sICAM-1 and sVCAM-1 as biomarkers in early and late stages of schizophrenia.
    Stefanović MP; Petronijević N; Dunjić-Kostić B; Velimirović M; Nikolić T; Jurišić V; Lačković M; Damjanović A; Totić-Poznanović S; Jovanović AA; Ivković M
    J Psychiatr Res; 2016 Feb; 73():45-52. PubMed ID: 26679764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pro/Antioxidant State as a Potential Biomarker of Schizophrenia.
    Juchnowicz D; Dzikowski M; Rog J; Waszkiewicz N; Karakuła KH; Zalewska A; Maciejczyk M; Karakula-Juchnowicz H
    J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redox and Immune Signaling in Schizophrenia: New Therapeutic Potential.
    Dwir D; Khadimallah I; Xin L; Rahman M; Du F; Öngür D; Do KQ
    Int J Neuropsychopharmacol; 2023 May; 26(5):309-321. PubMed ID: 36975001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.